The “Innovative Approach” of the Dog Aging Project May Have Hurt Its Odds for Renewed Funding

Veterinary medicine is less regulated than human medicine, and so trial and error experiments may allow faster innovation that would benefit both dogs and humans.

(p. D3) In late 2019, scientists began searching for 10,000 Americans willing to enroll their pets in an ambitious new study of health and longevity in dogs. The researchers planned to track the dogs over the course of their lives, collecting detailed information about their bodies, lifestyles and home environments. Over time, the scientists hoped to identify the biological and environmental factors that kept some dogs healthy in their golden years — and uncover insights about aging that could help both dogs and humans lead longer, healthier lives.

Today, the Dog Aging Project has enrolled 47,000 canines and counting, and the data are starting to stream in. The scientists say that they are just getting started.

“We think of the Dog Aging Project as a forever project, so recruitment is ongoing,” said Daniel Promislow, a biogerontologist at the University of Washington and a co-director of the project. “There will always be new questions to ask. We want to always have dogs of all ages participating.”

But Dr. Promislow and his colleagues are now facing the prospect that the Dog Aging Project might have its own life cut short. About 90 percent of the study’s funding comes from the National Institute on Aging, a part of the National Institutes of Health, which has provided more than $28 million since 2018. But that money will run out in June, and the institute does not seem likely to approve the researchers’ recent application for a five-year grant renewal, the scientists say.

“We have been told informally that the grant is not going to be funded,” said Matt Kaeberlein, the other director of the Dog Aging Project and a former biogerontology researcher at the University of Washington. (Dr. Kaeberlein is now the chief executive of Optispan, a health technology company.)

. . .

Steven Austad, a biogerontologist at the University of Alabama at Birmingham who is not part of the research team, said he was surprised that the researchers’ grant might not be renewed. “The importance of the things they publish and the depth of detail will increase over time, but I thought they got off to a really good start,” he said. “A large study like this really deserves a chance to mature.”

Dr. Austad’s miniature dachshund, Emmylou, is enrolled in the Dog Aging Project. But at 2 years old, he noted, Emmylou is “not going to teach them a lot about aging for a long time yet.”

The project’s innovative approach might have worked against it, Dr. Austad added. Reviewers accustomed to evaluating short-term research on lab mice and long-term studies of humans may not have known what to make of an enormous epidemiological study of pet dogs.

Whatever the reason, the refusal to commit to more funding is “wrong,” Dr. Kaeberlein said. “It’s just really, really difficult to justify this decision, if you look at the productivity and the impact of the project.”

That impact extends beyond the findings themselves, he added. “This project has engaged almost 50,000 Americans in biomedical scientific research.”

Over the last few years, Shelley Carpenter, of Gulfport, Miss., has provided the researchers with regular updates on and medical records for her Pembroke Welsh corgi, Murfee. (She also collected a cheek swab for genomic sequencing.) Ms. Carpenter, whose previous corgi died from a neurodegenerative disease similar to A.L.S., hoped that the project might produce new medical knowledge that could help both dogs and people.

For the full story see:

Emily Anthes. “Scientists Scramble to Keep Dog Aging Project Alive.” The New York Times (Tuesday, January 16, 2024): D3.

(Note: ellipses added.)

(Note: the online version of the story has the date Jan. 11, 2024, and has the same title as the print version.)

“A Plausible Case for Hounds in Heaven”

(p. A17) My mini bernedoodle, Sugaree, meets me at the door when she hears me on the front porch steps. She jumps in anticipation—all four legs catching air—until I enter the hallway. It’s a love that doesn’t diminish.

This is my welcome every weeknight when I come home from work. I haven’t split the atom, ended world hunger or even brought her a new chew toy, yet I am honored like Pompey the Great in his third Roman triumph.

. . .

British writer C.S. Lewis . . . in “The Problem of Pain,” . . . made a plausible case for hounds in heaven. Lewis thought sufficient selfhood might exist in dogs and other domesticated animals that their immortality is subsumed within their master’s heavenly destiny.

. . .

God surely has use for a creature that teaches us so much about love.

For the full commentary, see:

Mike Kerrigan. “Our Dog, Who Art in Heaven.” The Wall Street Journal (Thursday, Jan. 4, 2024): A17.

(Note: ellipses added.)

(Note: the online version of the commentary has the date January 3, 2024, and has the same title as the print version.)

The C.S. Lewis book mentioned above is:

Lewis, C. S. The Problem of Pain. San Francisco, CA: Harper One, 2001.

New Longevity Drugs for Dogs Can Be Proof-of-Concept for Longevity Drugs for People

(p. A1) “When you adopt a dog, you’re adopting future heartbreak,” said Emilie Adams, a New Yorker who owns three Rhodesian Ridgebacks. “It’s worth it over time because you just have so much love between now and when they go. But their life spans are shorter than ours.”

In recent years, scientists have been chasing after drugs that might stave off this heartbreak by extending the lives of our canine companions. On Tuesday, the biotech company Loyal announced that it had moved one step closer to bringing one such drug to market. “The data you provided are sufficient to show that there is a reasonable expectation of effectiveness,” an official at the U.S. Food and Drug Administration informed the company in a recent letter. (Loyal provided a copy of the letter to The Times.)

That means that the drug, which Loyal declined to identify for proprietary reasons, has met one of the requirements for “expanded conditional approval,” a fast-tracked authorization for ani-(p. A19)mal drugs that fulfill unmet health needs and require difficult clinical trials. The drug is not available to pet owners yet, and the F.D.A. must still review the company’s safety and manufacturing data. But conditional approval, which Loyal hopes to receive in 2026, would allow the company to begin marketing the drug for canine life extension, even before a large clinical trial is complete.

. . .

. . . the letter, which came after years of discussion between Loyal and the F.D.A., suggests that the agency is open to canine longevity drugs, Ms. Halioua said.

. . .

Aging may be an inevitability, but it is not an unyielding one. Scientists have created longer-lived worms, flies and mice by tweaking key aging-related genes.

These findings have raised the tantalizing possibility that scientists might be able to find drugs that had the same life-extending effects in people. That remains an active area of research, but canine longevity has recently started to attract more attention, in part because dogs are good models for human aging and in part because many pet owners would love more time with their furry family members.

“There’s not a lot you wouldn’t do if you could stack the deck in your favor to preserve the life of your hairy, four-legged child,” said Ms. Adams, the Rhodesian Ridgeback owner.

For the full story, see:

Emily Anthes. “A Drug Aims to Extend Dogs’ Lives, Yes It Does.” The New York Times (Saturday, November 29, 2023): A1 & A19.

(Note: ellipses, and bracketed year, added.)

(Note: the online version of the story was updated Nov. 29, 2023, and has the title “Could a Drug Give Your Pet More Dog Years?”)

Cancel Culture Comes for Odysseus

I took a couple of years of classical Greek in college from “Doc” Charles, a senior member of the Wabash College faculty. One year we read Homer’s The Odyssey; the other year we read Plato’s “Apology” and the Greek New Testament; I don’t remember for sure which we read first. But I think we read The Odyssey in the second year, when I was the only student in the course. I got credit for taking the course; but with only one student, Doc Charles did not get credit for teaching it. One of my abiding regrets is that I never took the time in later years to thank Doc Charles. When our daughter Jenny’s middle school class read a little bit of an English translation of The Odyssey, I grabbed my own copy of the English translation and read her a few paragraphs that I thought she would like. Jenny is partial to the dachshund breed of hound dogs. The paragraphs I read were about Odysseus finally entering Ithaca after 10 years of fighting the Trojan War and another 10 years of struggling to return home. After 20 years’ absence the first humans he meets do not recognize him. But an old hound dog who was his puppy when he left Ithaca, rises to its feet and wags its tail in greeting. The Odyssey is about loyalty and resilience and loving your hound dog. Created many centuries ago, it connects us to ancestors with whom we still share values, challenges, and hopes. Odysseus was a flawed hero but he was a hero. We should defend our right to read the story of his struggles.

(p. A15) A sustained effort is under way to deny children access to literature. Under the slogan #DisruptTexts, critical-theory ideologues, schoolteachers and Twitter agitators are purging and propagandizing against classic texts—everything from Homer to F. Scott Fitzgerald to Dr. Seuss.

. . .

The demands for censorship appear to be getting results. “Be like Odysseus and embrace the long haul to liberation (and then take the Odyssey out of your curriculum because it’s trash),” tweeted Shea Martin in June [2020]. “Hahaha,” replied Heather Levine, an English teacher at Lawrence (Mass.) High School. “Very proud to say we got the Odyssey removed from the curriculum this year!” When I contacted Ms. Levine to confirm this, she replied that she found the inquiry “invasive.”

For the full commentary, see:

Meghan Cox Gurdon. “Even Homer Gets Mobbed.” The Wall Street Journal (Monday, Dec. 28, 2020): A15.

(Note: ellipsis, and bracketed year, added.)

(Note: the online version of the commentary was updated Dec. 27, 2020, and has the same title as the print version.)

Do You Have to Be a Human to Have a Soul?

I cannot prove it to the skeptical, but after observing and interacting with our dachshund Willy almost every day for about 10 years, I strongly believe that he thinks and feels in ways that show he has a soul.
And I have no trouble believing that if a dachshund has a soul, then an elephant has one too.

(p. A21) Caitrin Nicol had an absorbing essay in The New Atlantis called “Do Elephants Have Souls?” Nicol quotes testimony from those who study elephant behavior. Here’s one elephant greeting a 51-year-old newcomer to her sanctuary:

“Everyone watched in joy and amazement as Tarra and Shirley intertwined trunks and made ‘purring’ noises at each other. Shirley very deliberately showed Tarra each injury she had sustained at the circus, and Tarra then gently moved her trunk over each injured part.”
Nicol not only asks whether this behavior suggests that elephants do have souls, she also illuminates what a soul is. The word is hard to define for many these days, but, Nicol notes, “when we talk about it, we all mean more or less the same thing: what it means for someone to bare it, for music to have it, for eyes to be the window to it, for it to be uplifted or depraved.”

For the full commentary, see:
DAVID BROOKS. “The Sidney Awards.” The New York Times (Fri., December 27, 2013): A18. [National Edition]
(Note: the online version of the commentary has the date December 26, 2013, and has the title “The Sidney Awards, Part 1.”)

The article praised by Brooks is:
Nicol, Caitrin. “Do Elephants Have Souls?” New Atlantis: A Journal of Technology & Society 38 (Winter/Spring 2013): 10-70.

Mary K. Fox

Jenny’s fourth and fifth grade teacher, Mary K. Fox, ended a long battle with cancer on January 30, 2006. Here are our “Guest Book” entries:
February 1, 2006
You were a great teacher. I will miss you very much. I remember the first day you met Willy (my dog). You liked him very much. Willy will always remember you, and think of you as Jenny’s teacher.
Love, Jenny (and Willy)
Jenny Diamond (Omaha, NE )
February 1, 2006
We admired Mary’s strength and determination; her patience and good will.
Art & Jeanette Diamond (Omaha, NE )

Willy and His Balls


Willy is a miniature dachshund. Willy’s veterinarian has from the start urged us to have him neutered, but we have so far resisted the temptation to follow the politically correct practice.
I did not attend Willy’s most recent visit to the vet, but I am told that he was placed on the counter and given two shots. Little Willy was not fond of this activity, so after receiving the second shot, he lifted up a hind leg and peed on the floor. Observing this, the vet said ‘that’s what you have to expect from an intact male.’
Willy’s favorite activity is to chase after a ball that you throw for him. His favorite balls are racquetballs, because they are small enough for him to easily carry around and because they have a lot of bounce. But he is also happy to chase tennis balls, and when he sees a soccer ball, he goes beserk with enthusiasm. (When my daughter and I practice soccer in the backyard, little Willy switches to whichever side is most in need of help.)
Our miniature dachshund is a loyal, intelligent, rascally, affectionate, stubborn critter. My advice to little Willy: don’t ever let them take away your balls.